BRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that it will present data on peanut allergy during poster sessions at two upcoming medical meetings.
ACAAI: At the American College of Asthma, Allergy and Immunology (ACAAI) Annual Scientific Meeting, taking place October 26-30, 2017, in Boston, Aimmune will present:
- #P338: “Current Management and Use of Oral Immunotherapy (OIT) for Peanut Allergy in U.S. Patients” (Presenting author: J. Lieberman), Friday, October 27.
- #P339: “International Comparisons of Patient Characteristics in a Phase 3 Study of AR101 for Peanut Allergy” (Presenting author: B. Vickery), Friday, October 27.
- #P340: “Practice Considerations in Offering Peanut Oral Immunotherapy (OIT) in the United States” (Presenting author: D. Petroni), Friday, October 27.
Aimmune will also host a Corporate Symposium, “From Diagnosis to Potential Future Oral Immunotherapeutic Options: Understanding the Burden and Risk of Avoidance in Peanut Allergy,” on Friday, October 27.
PAAM: At the European Academy of Allergy and Clinical Immunology’s Pediatric Allergy and Asthma Meeting (PAAM), taking place October 26-28, 2017, in London, Aimmune will present:
- #P104: “Current Management and Use of Oral Immunotherapy (OIT) for Peanut Allergy in Paediatric Patients in France, Germany, Italy, Spain, Switzerland and the United Kingdom” (Presenting author: A. Vereda), Friday, October 27.
Aimmune will also host a Corporate Symposium, “Peanut Allergy: Impact, Treatment and Defining Success,” on Friday, October 27.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, is developing treatments for life-threatening food allergies. Aimmune’s Characterized Oral Desensitization ImmunoTherapy (CODIT™) approach is intended to achieve meaningful levels of protection by desensitizing patients with defined, precise amounts of key allergens. Aimmune’s first investigational biologic product using CODIT™, AR101 for the treatment of peanut allergy, has received the FDA’s Breakthrough Therapy Designation for the desensitization of peanut-allergic patients 4-17 years of age and is currently being evaluated in Phase 3 clinical trials. For more information, please see www.aimmune.com.